200 related articles for article (PubMed ID: 38093196)
61. The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study.
Zhang Y; Lai S; Zhang J; Wang Y; Zhao H; He J; Huang D; Chen G; Qi Z; Chen P; Yan S; Huang X; Lu X; Zhong S; Jia Y
J Affect Disord; 2024 Apr; 351():799-807. PubMed ID: 38311073
[TBL] [Abstract][Full Text] [Related]
62. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
[TBL] [Abstract][Full Text] [Related]
63. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
Christensen MC; Florea I; Lindsten A; Baldwin DS
J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
[TBL] [Abstract][Full Text] [Related]
64. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial.
Cao B; Park C; Rosenblat JD; Chen Y; Iacobucci M; Subramaniapillai M; Mansur RB; Zuckerman H; Lee Y; McIntyre RS
J Psychopharmacol; 2019 Nov; 33(11):1388-1394. PubMed ID: 31530216
[TBL] [Abstract][Full Text] [Related]
65. Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder.
Kotzalidis GD; Lombardozzi G; Matrone M; Amici E; Perrini F; Cuomo I; De Filippis S
Curr Neuropharmacol; 2021; 19(12):2296-2307. PubMed ID: 33441069
[TBL] [Abstract][Full Text] [Related]
66. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
Findling RL; DelBello MP; Zuddas A; Emslie GJ; Ettrup A; Petersen ML; Schmidt SN; Rosen M
J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
[TBL] [Abstract][Full Text] [Related]
67. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
68. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
Fagiolini A; Florea I; Loft H; Christensen MC
J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
[TBL] [Abstract][Full Text] [Related]
69. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
[No Abstract] [Full Text] [Related]
70. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
[TBL] [Abstract][Full Text] [Related]
71. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
[TBL] [Abstract][Full Text] [Related]
72. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
[TBL] [Abstract][Full Text] [Related]
73. Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.
Levada OA; Troyan AS; Pinchuk IY
BMC Psychiatry; 2020 May; 20(1):208. PubMed ID: 32384884
[TBL] [Abstract][Full Text] [Related]
74. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
[No Abstract] [Full Text] [Related]
75. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
76. Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder.
Cuomo A; Barillà G; Cattolico M; Pardossi S; Mariantoni E; Koukouna D; Carmellini P; Fagiolini A
Expert Rev Neurother; 2024 May; 24(5):465-476. PubMed ID: 38536761
[TBL] [Abstract][Full Text] [Related]
77. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
Borhannejad F; Shariati B; Naderi S; Shalbafan M; Mortezaei A; Sahebolzamani E; Saeb A; Hosein Mortazavi S; Kamalzadeh L; Aqamolaei A; Ali Noorbala A; Namazi-Shabestari A; Akhondzadeh S
J Clin Pharm Ther; 2020 Aug; 45(4):804-811. PubMed ID: 32420649
[TBL] [Abstract][Full Text] [Related]
78. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
79. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
[TBL] [Abstract][Full Text] [Related]
80. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E
Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
